Asia Executives On The Move: BMS Names New China GM, New President For Nippon Kayaku
The coming of summer has seen a flurry of executive changes in the Asia Pacific biopharma sector. BMS has named a new China GM amid a fierce immuno-oncology battle, Parexel Japan has a new president, and other personnel changes take place at Nippon Kayaku, Zai Lab and Harbour BioMed.
You may also be interested in...
The Chinese firm regains all rights to tislelizumab ahead of the closing of Celgene’s merger with Bristol-Myers Squibb. BeiGene also forms cancer JV with US biotech SpringWorks.
A regulatory pathway set up in China post-SARS is under stress test in the latest coronavirus outbreak, while emergency measures adopted by the country's regulator mean it’s much less burdensome to obtain approvals than before.